Sun Pharma Gets DCGI Nod for Generic Semaglutide Injection for Weight Management
Sun Pharma received DCGI approval to manufacture and market a generic version of semaglutide injection in India for chronic weight management, to be sold under the brand name Noveltreat after patent expiry. The product, approved after Phase III trials in India, will come in five dose strengths, with a maintenance dose of 2.4 mg weekly. This follows Sun Pharma's December 2025 DCGI approval for semaglutide injection to treat type 2 diabetes.
The DCGI approval is a significant regulatory milestone that allows Sun Pharma to launch a new product in the Indian market, potentially addressing a growing health concern. However, the actual impact will depend on the market uptake and competition.
The announcement highlights a positive development for Sun Pharma with the DCGI approval for a new product, which can positively impact its revenue and market position.
Sun Pharmaceutical Industries Limited announced that it has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection in India for chronic weight management in adults as an adjunct to a reduced calorie diet and increased physical activity. The company will launch the product under the brand name Noveltreat after the expiry of the semaglutide patent in India. This approval follows a Phase III clinical trial conducted in India. Noveltreat will be available in five dose strengths: 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, and 2.4 mg/0.75 mL, with a maintenance dose of 2.4 mg once weekly, administered via a prefilled pen. 23 January 2026. The company received DCGI approval in December 2025 for manufacturing and marketing semaglutide injection for treating adults with type 2 diabetes, to be launched under the brand name Sematrinity after patent expiry.
Kirti Ganorkar, Managing Director of Sun Pharma, stated that obesity and diabetes are significant health challenges in India, and GLP-1 based therapies can play a meaningful role. He added that Noveltreat meets global quality standards and is supported by Indian clinical evidence.
Dr. Unnikrishnan A G, Chief Endocrinologist and CEO, Chellaram Diabetes Institute, noted that GLP-1 receptor agonists like semaglutide are an important advancement for metabolic health and should be combined with lifestyle measures under medical supervision, adding that improved accessibility will help address unmet needs.
What to do with a filing like this
Sun Pharmaceutical Industries Limited filed this with the NSE as a statutory disclosure, categorised under product launches. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sun Pharmaceutical Industries Limited. Read the original for the full detail.